Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway

Medical Hypotheses

Volumn 60, Issue 5, 2003, Pages 634-639

  McCarty, Mark F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; META TYROSINE; RAC1 PROTEIN; SERINE; STAT3 PROTEIN; STATIN;

ARTICLE; CARDIOVASCULAR RISK; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; ISOPRENYLATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0037403080     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00232-3     Document Type: Article

References (91)

1. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
2. Tracy R. P., Lemaitre R. N., Psaty B. M. et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
3. Ridker P. M., Buring J. E., Shin J., Matias M., Hennekens C. H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
4. Ridker P. M., Glynn R. J., Hennekens C. H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
5. Koenig W., Sund M., Frohlich M. et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
6. Albert M. A., Ridker P. M. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1999; 1: 99-104.
7. Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
8. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
9. Strandberg T. E., Vanhanen H., Tikkanen M. J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-119.
10. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001; 77: 247-253.
11. Ridker P. M., Rifai N., Lowenthal S. P. Rapid reduction in C-reactive protein with cerivastafin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
12. Jialal I., Stein D., Balis D., Grundy S. M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
13. Ridker P. M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
14. Albert M. A., Danielson E., Rifai N., Ridker P. M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
15. Gaw A. Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? Atherosclerosis 1996; 125: 267-269.
16. Vaughan C. J., Murphy M. B., Buckley B. M. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
17. Bellosta S., Bernini F., Ferri N. et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137: Suppl:S101-S109.
18. Sotiriou C. G., Cheng J. W. Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Ann Pharmacother 2000; 34: 1432-1439.
19. Laufs U., Liao J. K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000; 10: 143-148.
20. Laufs U., Liao J. K. Targeting Rho in cardiovascular disease. Circ Res 2000; 87: 526-528.
21. Endres M., Laufs U., Huang Z. et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885.
22. Laufs U., Liao J. K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271.
23. Laufs U., Marra D., Node K., Liao J. K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip 1). J Biol Chem 1999; 274: 21926-21931.
24. Wagner A. H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69.
25. Wassmann S., Laufs U., Baumer A. T. et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensm AT1 receptor expression and Racl GTPase. Mol Pharmacol 2001; 59: 646-654.
26. Hernandez-Perera O., Perez-Sala D., Soria E., Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616-622.
27. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J. D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-690.
28. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-562.
29. Seabra M. C. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal 1998; 10: 167-172.
30. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
31. Heinrich P. C., Horn F., Graeve L. et al. Interleukin-6 and related cytokines: effect on the acute phase reaction. Z Ernahrungswiss 1998; 37(Suppl 1): 43-49.
32. Deskur-Smielecka E., Wykr T. A., Kempa M., Furmaniuk J., Wysocki H. The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia. Coron Artery Dis 2001; 12: 143-148.
33. Fukuo Y., Nagashima M., Soya-Ohmura N., Takagi S., Terashi A., Ikejima T. Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/ macrophages. Nippon Ika Daigaku Zasshi 1995; 62: 386-390.
34. de Bont N., Netea M. G., Rovers C. et al. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 139: 147-152.
35. Massy Z. A., Kim Y., Guijarro C., Kasiske B. L., Keane W. F., O'Donnell M. P. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 2000; 267: 536-540.
36. Zhong Z., Wen Z., Darnell J. E. J. Stat3: a STAT family member activated by tyrosine phosphorylation m response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-98.
37. Cha-Molstad H., Agrawal A., Zhang D., Samols D., Kushner I. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 2000; 165: 4592-4597.
38. Wen Z., Zhong Z., Darnell J. E. J. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
39. Wen Z., Darnell J. E. J. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 1997; 25: 2062-2067.
40. Schindler C., Darnell J. E. J. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64: 621-651.
41. Schuringa J. J., Jonk L. J., Dokter W. H., Vellenga E., Kruijer W. Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/ MKK-4 as signal transduction components. Biochem J 2000; 347(Pt 1): 89-96.
42. Schuringa J. J., Dekker L. V., Vellenga E., Kruijer W. Sequential Activation of Rac-1, SEK-1/MKK-4, and Protein Kinase Cdelta Is Required for Interleukin-6-induced STAT3 Ser-727 Phosphorylation and Transactivation. J Biol Chem 2001; 276: 27709-27715.
43. Crespo P., Schuebel K. E., Ostrom A. A., Gutkind J. S., Bustelo X. R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the Vav proto-oncogene product. Nature 1997; 385: 169-172.
44. Crespo P., Bustelo X. R., Aaronson D. S. et al. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene 1996; 13: 455-460.
45. Jain N., Zhang T., Kee W. H., Li W., Cao X. Protein kinase C delta associates with and phosphorylates Star3 in an interleukin-6-dependent manner. J Biol Chem 1999; 274: 24392-24400.
46. Chung J., Uchida E., Grammer T. C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17: 6508-6516.
47. Pasceri V., Chang J., Willerson J. T., Yeh E. T. Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
48. Pasceri V., Willerson J. T., Yeh E. T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
49. Fichtlscherer S., Rosenberger G., Walter D. H., Breuer S., Dimmeler S., Zeiher A. M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006.
50. Fichtlscherer S., Zeiher A. M. Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann Med 2000; 32: 515-518.
51. Cermak J., Key N. S., Bach R. K, Balla J., Jacob H. S., Vercellotti G. M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
52. Ramani M., Khechai F., Ollivier V. et al. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett 1994; 356: 86-88.
53. Brand K., Page S., Walli A. K., Neumeier D., Baeuerle P. A. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997; 82: 297-304.
54. Thurberg B. L., Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998; 9: 387-396.
55. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S9-14.
56. Danesh J., Whincup P., Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
57. Ridker P. M., Rifai N., Pfeffer M. A. et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
58. Ridker P. M., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
59. Peng H. B., Libby P., Liao J. K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270: 14214-14219.
60. De Caterina R., Libby P., Peng H. B. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-68.
61. Peng H. B., Rajavashisth T. B., Libby P., Liao J. K. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995; 270: 17050-17055.
62. Spiecker M, Peng H. B., Liao J. K. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem 1997; 272: 30969-30974.
63. Spiecker M., Darius H., Kaboth K., Hubner F., Liao J. K. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol 1998; 63: 732-739.
64. Laroux F. S., Lefer D. J., Kawachi S. et al. Role of nitric oxide in the regulation of acute and chronic inflammation. Antioxid Redox Signal 2000; 2: 391-396.
65. Boger R. H., Bode-Boger S. M., Tsao P. S., Lin P. S., Chan J. R., Cooke J. P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295.
66. Zampolli A., Basta G., Lazzerini G., Feelisch M., De Caterina R. Inhibition of endothelial cell activation by nitric oxide donors. J Pharmacol Exp Ther 2000; 295: 818-823.
67. Theilmeier G., Chan J. R., Zalpour C. et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 1997; 17: 3557-3564.
68. Chan J. R., Boger R. H., Bode-Boger S. M. et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20: 1040-1046.
69. Cammarano M. S., Minden A. Db1 and the rho gtpases activate nfkappa b by ikappa b kinase (ikk)-dependent and ikk-independent pathways. J Biol Chem 2001; 276: 25876-25882.
70. Frost J. A., Swantek J. L., Stippec S., Yin M. J., Gaynor R., Cobb M. H. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem 2000; 275: 19693-19699.
71. Gnad R., Aktories K., Kaina B., Fritz G. Inhibition of protein isoprenylation impairs rho-regulated early cellular response to genotoxic stress. Mol Pharmacol 2000; 58: 1389-1397.
72. Montaner S., Perona R., Saniger L., Lacal J. C. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 1998; 273: 12779-12785.
73. Perona R., Montaner S., Saniger L., Sanchez-Perez I., Bravo R., Lacal J. C. Activation of the nuclear factor-kappa B by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11: 463-475.
74. Sulciner D. J., Irani K., Yu Z. X., Ferrans V. J., Goldschmidt-Clermont P., Finkel T. Rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappa B activation. Mol Cell Biol 1996; 16: 7115-7121.
75. Bustos C., Hernandez-Presa M. A., Ortego M. et al. HMG-CoA reductase inhibbition by atorvastatin reduce neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064.
76. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-272.
77. Dechend R., Fiebler A., Lindschau C. et al. Modulating angiotensin II-induced inflammation by HMG CoA reductase inhibition. Am J Hypertens 2001; 14: 55S-61S.
78. Gnad R., Kaina B., Fritz G. Rho GTPases are involved in the regulation of NF-kappa B by genotoxic stress. Exp Cell Res 2001; 264: 244-249.
79. Guijarro C., Kim Y., Schoonover C. M. et al. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant 1996; 11: 990-996.
80. Law R. E., Stimmel J. B., Damore M. A., Carter C., Clarke S., Wall R. Lipopolysaccharide-induced NF-kappa B activation in mouse70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5′-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions. Mol Cell Biol 1992; 12: 103-111.
81. Ortego M., Bustos C., Hernandez-Presa M. A. et al. Atorvastatin reduces NF-kappa B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-261.
82. Martin T., Cardarelli P. M., Parry G. C., Felts K. A., Cobb R. R. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur J Immunol 1997; 27: 1091-1097.
83. Hernandez F., Illnait J., Mas R. et al. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Therapeutic Res 1992; 51: 568-575.
84. Mas R., Castano G., Illnait J. et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999; 65: 439-447.
85. Castano G., Mas R., Fernandez J. C., Fernandez L., Alvarez E., Lezcay M. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Therapeutic Res 2000; 61: 137-146.
86. Castano G., Mas R., Arruzazabala M. L. et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999; 19: 105-116.
87. Castano G., Mas R., Fernandez J. C., Illnait J., Fernandez L., Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001; 56: M186-M192.
88. Castano G., Mas R., Fernandez J. C., Lopez L. E., Fernandez L. A long-term open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Therapeutic Res 1999; 60: 379-391.
89. Menendez R., Fernandez S. I., Del Rio A. et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203.
90. Menendez R., Amor A. M., Gonzalez R. M., Fraga V., Mas R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996; 29: 253-257.
91. Menendez R., Amor A. M., Rodeiro I. et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8-12.